IRCT20120215009014N484尚未招募3 期
Effect of Empagliflozin as adjunctive therapy versus placebo on serum level of oxidative stress biomarkers in diabetic patients with systolic heart failure: a double-blind randomized clinical trial
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 80 years（—）
- 性别
- All
入选标准
- •Age 18 to 80 years
- •Type 2 diabetes
- •Controlled systolic heart failure for at least 6 months
- •Hemoglobin A1c less than 6.5
- •Stable clinical and hemodynamic status
排除标准
- •Pregnancy or breastfeeding
- •Inflammatory, respiratory, infectious or malignant diseases
- •History of myocardial infarction, stroke, angioplasty or CABG in the last 3 months
- •Embedding pacemaker in the last 3 months
- •Use of anti-oxidant or anti-inflammatory drugs or corticosteroids in the last 3 months
研究者
相似试验
尚未招募
3 期
Effect of Empagliflozin as adjunctive therapy on serum level of oxidative stress biomarkersIRCT20120215009014N486Hamedan University of Medical Sciences80
尚未招募
3 期
Comparison of therapeutic effect of Empagliflozin (Gloripa) and Sitagliptin (Ziptin) on type 2 Diabetic patientsIRCT20200810048355N1Vice Chancellor for Research, Islamic Aazad University, Najafabad branch128
已完成
Unknown
Evaluation of the effect of empagliflozin in combination with pioglitazone on fatty liver diseaseFatty liver.Fatty (change of) liver, not elsewhere classifiedK76.0IRCT20240208060939N1Artesh University of Medical Sciences80
招募中
3 期
Effect of Empagliflozin in PrediabetesCondition 1: Impaired fasting glucose. Condition 2: Impaired glucose tolerance.Impaired fasting glucoseImpaired glucose tolerance (oral)R73.01R73.02IRCT20220902055858N1Shahre-kord University of Medical Sciences90
尚未招募
3 期
Assessment of effectiveness of Empagliflozin in the management of Anemia in diabetes patientsCTRI/2024/02/063292SRM Insitute of Science and Technology